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Original Article
Antiretroviral Therapy Initiation 
Following Policy Changes: 
Observations From China
Li Li, PhD1, Guoping Ji, PhD2, Chunqing Lin, PhD1,  
Li-Jung Liang, PhD1, and Chiao-Wen Lan, MPH1
Abstract
China’s HIV/AIDS treatment policies have been evolving over the preceding decade. This study 
describes patterns of antiretroviral therapy (ART) initiation for a sample of people living with 
HIV/AIDS (PLHIV) in rural Anhui, China, where most PLHIV were infected via paid plasma 
donation during the 1990s. A total of 481 PLHIV who were receiving ART were included in our 
analyses. Times between HIV diagnosis and the initiation of ART were examined relative to the 
time points when major ART-related policies changed in China. More than half (53%) of PLHIV 
who had been diagnosed by 2003 received ART within 6 months, whereas 93% of PLHIV who 
had been diagnosed in 2010 or later received ART within 6 months. The study results provide 
additional support that the “Four Frees and One Care” policy in 2003 and the relaxation of ART 
eligibility in 2010 have facilitated the initiation of treatment for PLHIV in China.
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Introduction
The HIV epidemic began in China during the prior century, after the first case of AIDS in China was 
identified in 1985.1 By the end of 2014, there were 501,000 reported people living with HIV 
(PLHIV) in China.2 China’s responses to the HIV/AIDS epidemic have been evolving over time; in 
particular, treatment policies have changed. In 2002, China initiated and implemented a pilot com-
munity-based free HIV treatment, care, and prevention program named China CARES; this pilot 
program was subsequently expanded to the entire nation in 2003 and became the current National 
Free Antiretroviral Treatment Program (NFATP).3,4 In 2003, the Chinese government implemented 
a national HIV/AIDS policy, “Four Frees and One Care,” to provide free antiretroviral drugs to 
PLHIV who are rural residents or uninsured urban residents.5-8 The Four Frees and One Care pro-
gram significantly expanded access to antiretroviral therapy (ART) in China, resulting in an increase 
of 23,000 in the number of PLHIV enrolled in this program between 2005 and 2007.3,9
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In 2005, ART services in China were again scaled up as the government began to provide 
provincial-level plans.10 In 2006, China officially announced the first legislation directly 
aimed at controlling HIV/AIDS.11 By December 2006, highly active ART (HAART) coverage 
for former plasma donors with AIDS had reached 70.5%, with an accompanying decrease in 
mortality.12 In addition to improving the accessibility and reach of ART, the World Health 
Organization (WHO) issued new treatment guidelines for ART in 2011 that specified a cutoff 
point of a CD4 count of 350 cells/mm3 for beginning ART.13 This guidance led to a change in 
the national treatment guidelines for initiating ART in China, allowing an even greater num-
ber of PLHIV to obtain HIV-related treatment and care.14
However, the implications of China’s policy changes regarding ART initiation remain under-
studied, particularly among rural subsamples. With the rapid scaling up of HIV treatment and 
care in recent years, it is imperative to understand the impact of HIV policies on the initiation of 
treatment for PLHIV. This study describes a sample of PLHIV living in rural Anhui, China, who 
are currently receiving ART, focusing on the initiation of treatment for these individuals during 
various timeframes involving policy changes.
Methods
Study Sample
This study used baseline data from a randomized controlled trial for HIV-affected families in 
Anhui Province, China. Most existing HIV infections in Anhui were caused by commercial 
plasma donations during the early 1990s.15 Thousands of commercial plasma collection centers 
were established in rural China between 1990 and 1994,1 and donating blood to earn money 
became an easy method by which rural farmers augmented their incomes. In particular, plasma 
donors were paid to donate blood; during blood donations, plasma was removed, and red blood 
cells were intravenously reinjected into donors to prevent anemia caused by repeat blood dona-
tion. HIV-1 antibody testing was not required prior to 1995 and therefore was not performed at 
any local plasma collection center during the early 1990s.1 The mixing during collection and 
reinfusion led to thousands of new HIV infections among commercial plasma donors in Anhui.16 
Although these practices were stopped long ago, the history of this HIV outbreak among former 
plasma donors continues to affect the region. In this area, new cases of HIV infection have been 
diagnosed among children and among adults with no history of plasma donation, suggesting that 
transmission to populations other than plasma donors via sex, mother-to-child transmission, and 
injection drug use has already occurred.16,17
Data Collection
Data were collected between late 2011 and early 2013 from 32 villages within the 4 counties of 
Anhui. To recruit PLHIV, informational flyers regarding the study were posted in village clinics 
that were frequently visited by PLHIV for routine check-ups and care. Service providers at clin-
ics also disseminated study information to potential participants verbally and via informational 
materials. PLHIV interested in participating in the study were referred to a project recruiter who 
subsequently met privately with each potential study subject in a room of the village clinic or at 
the subject’s preferred location. During this meeting, the study recruiter screened the potential 
participant for eligibility, explained the study procedures, answered questions, emphasized the 
voluntary nature of participation, and obtained informed consent. A total of 522 PLHIV were 
included in this study.
Assessments were administered by computer-assisted personal interview (CAPI). Trained 
interviewers read the questions shown on a screen to the participant and entered their answers 
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directly into a computer database. The data collection process required approximately 45 to 60 
minutes for each participant. Each participant received 50 yuan (US$8) for completing the assess-
ment. The study protocol was approved by the institutional review boards of the Anhui Provincial 
Center for Disease Control and Prevention and the University of California, Los Angeles.
Measures
In this study, subjects’ sociodemographic characteristics, including age, gender, years of educa-
tion, and annual family income (in yuan) were collected. For PLHIV in China, CD4 counts and 
viral loads are routinely assessed every 6 months.18 During this study, no additional biomedical 
tests were performed. With participants’ consent, subjects’ medical records were examined and 
various clinical data were obtained, including dates of HIV diagnoses, dates when ART was initi-
ated, CD4 counts, CD4 testing dates, and viral loads. For each participant, project staff recorded 
a CD4 count, viral load test dates, and the results of tests conducted closest to the survey date. 
Continuous viral load data were dichotomized into the categories of undetectable and detectable 
viral RNA (with a threshold of 50 copies per mL of blood).19 The year of HIV diagnosis was 
divided into 4 categories: 2003 and earlier, 2004-2005, 2006-2009, and 2010 and later. These 
categories reflect major changes in HIV policies and treatment guidelines in China. To measure 
adherence to ART, participants were asked whether they had ever forgotten to take their ART 
medication. Subjects who responded affirmatively were further questioned regarding the number 
of day(s) they had not taken their ART medication during the past 7 and 30 days. A dichotomous 
measure was constructed in which a score of 1 was assigned if a participant reported ever stop-
ping their medicine and a score of 0 was assigned if a participant had not forgotten to take ART 
during the preceding 7- and 30-day periods.
Data Analysis
Demographic and clinical characteristics of the HIV-positive participants who were enrolled in 
the study and currently receiving ART treatment were summarized using descriptive statistics 
(means and standard deviations) for continuous data and frequencies for categorical data. The 
frequencies of PLHIV who received their ART treatments within 6 months of HIV diagnosis 
across the 4 HIV-diagnosis intervals described above were graphically examined, and compared 
without and with accounting for the clustering at the village level using chi-square and Cochran-
Mantel-Haenszel tests, respectively. All descriptive analyses were performed using SAS soft-
ware (SAS Institute, Cary, NC, USA).
Results
Demographic and ART-Related Characteristics
A total of 522 PLHIV participated in this trial, and 481 of these participants were receiving ART 
when they enrolled in the study. Participants’ demographic and ART-related characteristics are 
presented in Table 1. Subjects’ average age was 48.6 years, with 68% of participants between 36 
and 55 years of age. Less than half of the study sample (45%) was male. Participants’ average 
annual family income was 14,598 yuan (US$2383), which was lower than the average family 
income in Anhui Province in 2013 (25, 006 yuan or US$4,024).20 More than 40% of subjects 
were illiterate, and 13% of participants had received more than 6 years of education (Table 1).
Among the 481 PLHIV who were receiving ART at enrollment, the earliest HIV diagnosis 
was in 1996 and the latest HIV diagnosis was in 2013. Among these PLHIV, 239 subjects (50%) 
had been diagnosed by 2003, and 152 PLHIV (34%) had begun ART by 2003. More than 70% of 
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Table 1. Demographic and Antiretroviral Therapy (ART)–Related Characteristics of Study Participants.a
Characteristics n %
No. of participants (n = 522)
 On ART 481 92.1
 Not on ART 41  7.9
Demographic characteristics (n = 481)
Age (years)
 18-35 26 5.41
 36-45 164 34.1
 46-55 165 34.3
 >55 126 26.2
Male 216 44.9
Education (years)
 None 197 41.0
 0-6 222 46.2
 >6 62 12.9
Family income (yuan)
 <5000 68 14.2
 5001-10 000 108 22.6
 10 000-20 000 161 33.6
 >20 000 142 29.6
ART-related characteristics (n = 481)
Viral load
 Mean (SD) 10,185 (69,051)
 <50 325 71.1
 ≥50 132 28.9
CD4
 Mean (SD) 409 (210)
 <200 72 15.4
 200-350 129 27.6
 350-500 131 28.1
 ≥500 135 28.9
HIV diagnosis (year)
 2003 or earlier 239 49.9
 2004-2005 166 34.7
 2006-2009 57 11.9
 2010 or later 17  3.5
ART initiation (year)
 2003 or earlier 152 33.8
 2004-2005 114 25.3
 2006-2009 134 29.8
 2010 or later 50 11.1
Months between diagnosis and ART, mean (SD) 22.2 (28.8)
ART adherence (n = 481)
 Never forgotten to take ART medication 295 61.3
 Never missed a day of ART in the past 7 days 451 93.8
 Never missed a day of ART in the past 30 days 402 83.6
aNumber of missing values varied across demographic and clinical characteristics.
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PLHIV had undetectable viral loads, and 57% of PLHIV had CD4 counts greater than 350 cells/
mm3. More than 60% of PLHIV reported that they had never forgotten to take their ART medica-
tion, and about 84% of PLHIV had always remembered to take their ART medication during the 
preceding 30 days. Figure 1 presents the distribution of time intervals between HIV diagnosis 
and ART initiation across four HIV-diagnosis intervals. Thirty-one (6%) PLHIV had either miss-
ing HIV diagnosis or ART initiation dates. More than half (53%) of PLHIV who had been diag-
nosed by 2003 began receiving ART within 6 months, whereas 93% of PLHIV who had been 
diagnosed in 2010 or later began receiving ART within 6 months. Differences in the distributions 
of PLHIV who had their ART initiation within 6 months of HIV diagnosis across the four policy-
related intervals were statistically significant without and with accounting for the village-level of 
clustering (p < .001 and p = .022, respectively).
Discussion
This study described the condition of PLHIV receiving ART by examining their treatment initiation 
patterns in rural Anhui, China. We observed that the pattern of individual treatment initiation was 
associated with the time of HIV diagnosis, suggesting there might be a connection with changes in 
HIV treatment policies. Globally, recommendations regarding initiating therapy for asymptomatic 
HIV-infected patients have undergone major alterations over time.21 It appears that China’s decision 
to adhere to WHO treatment guidelines resulted in an increase in the early initiation of treatment 
among PLHIV. In addition, this increase could also be attributed to the implementation of the “Four 
Frees and One Care” program, which provides free ART to rural and poor urban residents,3 includ-
ing PLHIV enrolled in this study. This study provided further evidence illustrating the impact of 
ART expansion at the policy level on the treatment experiences of individual PLHIV. In 2014, 
Figure 1. Interval between HIV diagnosis and antiretroviral therapy (ART) initiation stratified by the 
time of HIV diagnosis.
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China again updated its national ART guidelines to a threshold CD4 count of 500 cells/mm3 to 
further ease ART initiation eligibility.22,23 Based on the findings of our study, we predict that this 
change will further facilitate the initiation of ART for more PLHIV in China.
Our findings should be interpreted in light of several limitations. First, the single group cross-
sectional design was a major limitation of the study, which restricted the ability to make between-
group comparisons and causality inferences. Second, most existing HIV infections in the 
examined region were caused by commercial plasma donations during the early 1990s; this situ-
ation may not be representative of conditions in other areas of China. Another limitation of this 
study was that no blood samples were collected to perform CD4/viral load testing. Instead, these 
data were obtained from patients’ medical records; therefore, there could be a lag between the 
collection of biomedical data and the time when our survey was conducted. Last, the sample size 
was limited, that is, the sample sizes for the later intervals (2010 and after) were relatively small. 
Nevertheless, the study findings indicate the impact of HIV policies on the early initiation of 
treatment. China is one of the few low- and middle-income countries in which domestic funds are 
the major source of HIV/AIDS program funding,24 and policy makers can use these findings to 
prioritize HIV-related health services and ensure that sufficient resources are committed to HIV 
care to curb the HIV epidemic in China.
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